by Idiopathic hypersomnia, also known as long sleeping disorder, involves excessive daytime sleepiness that is not caused by another condition. It results in prolonged or extended nighttime sleep as well as inability to stay awake and alert during the day despite adequate or prolonged nighttime sleep. The treatment options for idiopathic hypersomnia aim to reduce excessive daytime sleepiness and improve alertness during waking hours. Stimulants and wakefulness-promoting agents are commonly prescribed to patients suffering from idiopathic hypersomnia.
The global Idiopathic Hypersomnia Treatment Market is estimated to be valued at US$ 338.42 Mn in 2023 and is expected to exhibit a CAGR of 8.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing awareness about idiopathic hypersomnia disorder is driving the growth of idiopathic hypersomnia treatment market. Earlier, excessive daytime sleepiness was often dismissed as laziness. However, increased awareness among patients and physicians about this long-sleeping disorder has led to prompt diagnosis and treatment seeking behavior. This has significantly boosted demand for approved drug therapies for idiopathic hypersomnia over the past few years. Continuous efforts by support community organizations to increase public understanding of idiopathic hypersomnia are further expected to promote early treatment and management of the condition.
SWOT Analysis
Strength: The high unmet medical need for treatment of idiopathic hypersomnia represents a significant opportunity. Growing prevalence of this sleep disorder is driving research and development efforts.
Weakness: Current treatment options only provide symptomatic relief and lack efficacy against the underlying pathophysiology. Most of the pipeline drugs are still in early stages of development and approval is uncertain.
Opportunity: If approved, new mechanism-based therapies can capture a large share of the market and set new standards of care. Favourable regulations support the clinical evaluation of innovative treatment approaches.
Threats: Stringent regulatory pathways can delay market access or lead to program failures. Intense competition from other sleep disorder medications poses challenges. Safety and tolerability issues with new entities may limit their adoption.
Key Takeaways
The Global Idiopathic Hypersomnia Treatment Market Size is expected to witness high growth. The annual growth rate is projected to be around 8.7% during the forecast period of 2023 to 2030. The total market size for 2023 is estimated at US$ 338.42 million.
North America currently dominates the market owing to increasing idiopathic hypersomnia prevalence, supportive insurance policies, strong reimbursement structure, and robust research initiatives in the region. The Asia Pacific region is anticipated to grow at the fastest pace due to rising awareness, growing healthcare infrastructure, and large patient pool.
Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Jazz Pharmaceuticals, Inc. are some of the prominent players in the global market. They have broad product portfolios and advanced pipelines targeting idiopathic hypersomnia. Other notable companies include BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, and Merck & Co. Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
